Extraskeletal Myxoid Chondrosarcoma — Variants & evidence

Extraskeletal Myxoid Chondrosarcoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NR4A3 Fusion2
Pazopanib	Predictive	B	Supports Sensitivity Response	3	submitted	EID9819 In this single-arm, open-label phase 2 trial, extraskeletal myxoid chondrosarcoma patients treated with pazopanib were reported and 22/23 patients (one patient died before the primary analysis) were e… (full text at CIViC) PMID 31331701 · Stacchiotti et al., 2019 · Open in CIViC	civic
Sunitinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID6378 his report confirms the therapeutic activity of sunitinib in extraskeletal myxoid chondrosarcoma. Genotype/phenotype analyses support a correlation between response and EWSR1-NR4A3 fusion. PMID 24703573 · Stacchiotti et al., 2014 · Open in CIViC	civic
NR4A3 Fusion + NR4A3 Fusion1
Trabectedin	Predictive	C	Supports Sensitivity Response	2	accepted	EID12545 In a sub-analysis of a randomized phase II trial in extraskeletal myxoid chondrosarcoma (EWSR1-NR4A3 and TAF15-NR4A3 fusions; n = 2) and mesenchymal chondrosarcoma (HEY1-NCOA2 fusion, n = 6)(trabected… (full text at CIViC) PMID 27418251 · Morioka et al., 2016 · Open in CIViC	civic

Data updated 7 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.